Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 22:06 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Effect of Guanfacine on the Reversal of Opioid-induced Hyperalgesia (OIH)
NCT02192398 · Massachusetts General Hospital · NA · terminated · last registry update 2026-07-06 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “End of NIH funding” | – | Registry record, Massachusetts General Hospital |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against ADRA2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-28Also stopped (terminated): Algemeen Ziekenhuis Maria Middelares, Plasma-lyte (static group) + Norepinephrine (static group) (NCT06080178)
- 2026-10-28Also stopped (withdrawn): Aarhus University Hospital, Weak steroid (Flurolon, Allergan) + Potent steroid (Maxidex, Alcon) (NCT01682421)
- 2026-10-05Results posted on the registry: Ankara City Hospital Bilkent, Sevoflurane (Volatile Anesthetic) + Propofol 1% (NCT07092046)
- 2026-09-21Also stopped (withdrawn): University Ghent, a drug against ADRA2A (NCT06810674)
- 2026-09-10Phase 3 first posted: Cairo University, Insulin eye drops + standard post-operative topical drops (NCT07812129)
- 2026-08-05Results posted on the registry: Bausch & Lomb Incorporated, a drug against ADRA2A (NCT04840563)
- 2026-06-09Results posted on the registry: Johns Hopkins University, Lofexidine + Placebo (NCT04325659)
- 2026-05-22Results posted on the registry: Johnson & Johnson Vision Care, Inc., a drug against ADRA2A (NCT06749496)
- 2026-04-22Results posted on the registry: Beaver-Visitec International, Inc., a drug against ADRA2A (NCT06399211)
- 2026-04-14Results posted on the registry: University of Michigan, Carbidopa 25 mg + Carbidopa-Levodopa 25/100 mg (NCT06587217)
- 2026-03-19Also stopped (withdrawn): Centre hospitalier de l'Université de Montréal (CHUM), a drug against ADRA2A (NCT05119270)
- 2025-12-23Phase 3 first posted: Ain Shams University, Balanced anesthesia + Lidocaine spray (NCT07299630)
- 2025-12-11Also stopped (terminated): Hopital Charles Nicolle, Ephedrine (6 mg boluses) + Norepinephrine (10 µg boluses) (NCT07259655)
- 2025-09-16Also stopped (withdrawn): Alcon Research, a drug against ADRA2A (NCT06592521)
- 2025-09-03Phase 3 first posted: University Hospital Tuebingen, LECIG (levodopa, carbidopa, entacapone intestinal gel) + Best oral medication (NCT07151378)
- 2025-08-01Also stopped (withdrawn): USWM, LLC (dba US WorldMeds), LUCEMYRA (lofexidine) tablets (NCT06711640)
- 2025-07-23Also stopped (withdrawn): Walter Reed Army Medical Center, a drug against ADRA2A (NCT00412295)
- 2025-07-18Results posted on the registry: University of Michigan, carbidopa/levodopa, as prescribed by treating physician (NCT04821830)
- 2025-07-17Results posted on the registry: Laboratorios Sophia S.A de C.V., Naphazoline / Hypromellose Ophthalmic (NCT05470868)
- 2025-07-16Results posted on the registry: Laboratorios Sophia S.A de C.V., Nanodrop® + Systane Balance (NCT04111965)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision